The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

BACKGROUND: Levetiracetam and zonisamide are licensed as monotherapy for patients with focal epilepsy, but there is uncertainty as to whether they should be recommended as first-line treatments because of insufficient evidence of clinical effectiveness and cost-effectiveness. We aimed to assess the...

詳細記述

保存先:
書誌詳細
出版年:Lancet
主要な著者: Marson, Anthony, Burnside, Girvan, Appleton, Richard, Smith, Dave, Leach, John Paul, Sills, Graeme, Tudur-Smith, Catrin, Plumpton, Catrin, Hughes, Dyfrig A, Williamson, Paula, Baker, Gus A, Balabanova, Silviya, Taylor, Claire, Brown, Richard, Hindley, Dan, Howell, Stephen, Maguire, Melissa, Mohanraj, Rajiv, Smith, Philip E
フォーマット: Artigo
言語:Inglês
出版事項: Elsevier 2021
主題:
Articles
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8047799/
https://ncbi.nlm.nih.gov/pubmed/33838757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(21)00247-6
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料